Enanta Pharmaceuticals, Inc. (ENTA) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Enanta Pharmaceuticals, Inc. (ENTA) Bundle
Discover the true value of Enanta Pharmaceuticals, Inc. (ENTA) with our professional-grade DCF Calculator! Adjust key assumptions, explore various scenarios, and assess how different changes affect the valuation of Enanta Pharmaceuticals, Inc. (ENTA) – all in a comprehensive Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 122.5 | 97.1 | 86.2 | 79.2 | 67.6 | 58.4 | 50.4 | 43.5 | 37.6 | 32.4 |
| Revenue Growth, % | 0 | -20.74 | -11.24 | -8.07 | -14.61 | -13.67 | -13.67 | -13.67 | -13.67 | -13.67 |
| EBITDA | -38.0 | -104.2 | -119.2 | -123.5 | -104.5 | -50.3 | -43.5 | -37.5 | -32.4 | -28.0 |
| EBITDA, % | -31.02 | -107.39 | -138.36 | -155.9 | -154.52 | -86.2 | -86.2 | -86.2 | -86.2 | -86.2 |
| Depreciation | 3.6 | 3.3 | 3.0 | 2.4 | 2.3 | 1.9 | 1.6 | 1.4 | 1.2 | 1.1 |
| Depreciation, % | 2.98 | 3.43 | 3.45 | 2.99 | 3.45 | 3.26 | 3.26 | 3.26 | 3.26 | 3.26 |
| EBIT | -41.6 | -107.6 | -122.2 | -125.8 | -106.8 | -50.7 | -43.8 | -37.8 | -32.6 | -28.2 |
| EBIT, % | -34 | -110.82 | -141.82 | -158.89 | -157.98 | -86.8 | -86.8 | -86.8 | -86.8 | -86.8 |
| Total Cash | 386.6 | 244.0 | 249.2 | 369.9 | 248.2 | 58.4 | 50.4 | 43.5 | 37.6 | 32.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 23.5 | 60.8 | 49.0 | 39.6 | 6.6 | 23.2 | 20.0 | 17.3 | 14.9 | 12.9 |
| Account Receivables, % | 19.18 | 62.66 | 56.91 | 50.02 | 9.83 | 39.72 | 39.72 | 39.72 | 39.72 | 39.72 |
| Inventories | .0 | -37.3 | .0 | .0 | .0 | -4.5 | -3.9 | -3.3 | -2.9 | -2.5 |
| Inventories, % | 0 | -38.38 | 0 | 0 | 0 | -7.68 | -7.68 | -7.68 | -7.68 | -7.68 |
| Accounts Payable | 5.7 | 9.5 | 6.0 | 4.1 | 8.0 | 4.5 | 3.9 | 3.3 | 2.9 | 2.5 |
| Accounts Payable, % | 4.68 | 9.83 | 6.96 | 5.17 | 11.83 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 |
| Capital Expenditure | -1.4 | -.8 | -2.1 | -9.1 | -17.9 | -5.0 | -4.3 | -3.7 | -3.2 | -2.8 |
| Capital Expenditure, % | -1.18 | -0.77261 | -2.47 | -11.44 | -26.54 | -8.48 | -8.48 | -8.48 | -8.48 | -8.48 |
| Tax Rate, % | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 |
| EBITAT | -43.0 | -79.0 | -121.8 | -128.6 | -105.3 | -47.8 | -41.3 | -35.6 | -30.8 | -26.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -58.6 | -72.7 | -149.9 | -127.7 | -84.0 | -66.4 | -42.0 | -36.2 | -31.3 | -27.0 |
| WACC, % | 10.96 | 9.36 | 10.93 | 10.96 | 10.87 | 10.62 | 10.62 | 10.62 | 10.62 | 10.62 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -158.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -28 | |||||||||
| Terminal Value | -320 | |||||||||
| Present Terminal Value | -193 | |||||||||
| Enterprise Value | -351 | |||||||||
| Net Debt | 18 | |||||||||
| Equity Value | -370 | |||||||||
| Diluted Shares Outstanding, MM | 21 | |||||||||
| Equity Value Per Share | -17.47 |
What You Will Get
- Editable Forecast Inputs: Effortlessly modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Enanta Pharmaceuticals, Inc.'s (ENTA) financial data pre-loaded to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you automatically.
- Customizable and Professional: A sleek Excel model tailored to fit your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Enanta Pharmaceuticals, Inc. (ENTA).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to the pharmaceutical sector.
- Customizable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates to fit Enanta's financial outlook.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Enanta Pharmaceuticals, Inc. (ENTA).
- Visual Dashboard and Charts: Present visual summaries of key valuation metrics for straightforward analysis and decision-making.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Enanta Pharmaceuticals' pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for Enanta Pharmaceuticals, Inc. (ENTA)?
- Accurate Data: Utilize real Enanta Pharmaceuticals financials for dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: Easy-to-navigate design and step-by-step guidance cater to users of all experience levels.
Who Should Use This Product?
- Investors: Assess the fair value of Enanta Pharmaceuticals (ENTA) to inform your investment choices.
- CFOs: Utilize a high-quality DCF model for accurate financial reporting and analysis related to Enanta Pharmaceuticals (ENTA).
- Consultants: Efficiently modify the template for client valuation reports involving Enanta Pharmaceuticals (ENTA).
- Entrepreneurs: Discover financial modeling techniques employed by leading pharmaceutical companies, including Enanta Pharmaceuticals (ENTA).
- Educators: Implement it as a resource for teaching valuation methods in the context of Enanta Pharmaceuticals (ENTA).
What the Template Contains
- Pre-Filled DCF Model: Enanta Pharmaceuticals’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Enanta Pharmaceuticals’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.